Last reviewed · How we verify
Hydroxychloroquine Only Product in Oral Dose Form
At a glance
| Generic name | Hydroxychloroquine Only Product in Oral Dose Form |
|---|---|
| Sponsor | University of Malaga |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? (PHASE4)
- A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants (PHASE1)
- Trial of Treatments for COVID-19 in Hospitalized Adults (PHASE3)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC) (PHASE2)
- Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 (NA)
- Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: